Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease May 2021 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Com ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations & Corporate Communications Bryan Stuart - President & Chief Executive Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance & Accounting Conference Call Participants Kelly Girskis - SVB Leerink Ted Tenthoff - Piper Sandler Kostas Biliouris - Morgan Stanley Tazeen Ahmad - Bank of America Operator Good morning, a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Emerging growth company ☒ If an emerging ...

Fulcrum | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease March 2021 | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the dev ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2020 Results Earnings Conference Call March 4, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations and Corporate Communications Robert Gould - President & CEO Bryan Stuart - Chief Operating Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance and Accounting Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Dae Gon Ha - Stifel Matthew Harrison - Morgan Stanley O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its Charter) Delaware 47-4839948 (State or other jurisdict ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Christi Waarich - Director, Corporate Communications & IR Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Kostas Biliouris - Morgan Stanley Operator Good morning, and welcome to the Ful ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other j ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease September 2020 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development statu ...

Fulcrum | --- | --- | --- | --- | --- | --- | |---------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fulcrum Q2 2020 Conference Call | | | | | | | August 11, 2020 | | | | | | | | | | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regard ...